[1] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China(中华人民共和国药典一部,2020年版)[M]. Beijing: China Medical Science Press,2020. [2] GONG PH, YANG Y, LIU YT, et al.Research progress on chemical components of Cannabis Sativa and their pharmacological effects[J]. Chin J Experim Trad Med Formul(中国实验方剂学杂志), 2017, 23(13): 212-219. [3] HILL A, WILLIAMS C, WHALLEY B, et al.Phytocannabinoids as novel therapeutic agents in CNS disorders[J]. Pharmacol & Therap, 2012, 133(1): 79-97. [4] LI J, ZHU X, WAN H, et al.Progress on chemical constituents and analytical methods of cannabinoids in Cannabis sativa[J]. Chin Trad HerbDrugs(中草药), 2020, 51(24): 6414-6425. [5] KAPLAN J, STELLA N, CATTERALL W, et al.Cannabidiol attenuates seizures and social deficits in a mouse model of dravet syndrome[J]. Proc National Acad Sci USA, 2017, 114(42): 11229-11234. [6] GUGLIANDOLO A, SILVESTRO S, CHIRICOSTA L, et al.The transcriptomic analysis of NSC-34 motor neuron-like cells reveals that cannabigerol influences synaptic pathways: a comparative study with cannabidiol[J]. Life-Basel, 2020, 10(10): 227. [7] LAPRAIRIE R, BAGHER A, KELLY M, et al.Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor[J]. Brit J Pharm, 2015, 172(20): 4790-4805. [8] SUN YS.An overview of new drugs approved in the US and EU in June 2018[J]. Prog Pharm Sci(药学进展), 2018, 42(7): 551-553. [9] WANG X, YU J.Antitumor effects of cannabidiol and its molecular mechanism:research advances[J]. J Int Pharm Res(国际药学研究杂志), 2020, 47(12): 1057-1061,1077. [10] MASSI P, VACCANI A, BIANCHESSI S, et al.The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells[J]. Cell Mol Life Sci, 2006, 63(17): 2057-2066. [11] KOZELA E, KRAWCZYK M, KOS T, et al.Cannabidiol improves cognitive impairment and reverses cortical transcriptional changes induced by ketamine in schizophrenia-like model in rats[J]. Mol Neurobiol, 2020, 57(3): 1733-1747. [12] MAJOR-MONFRIED H, RENTERIA A, PAWARODE A, et al.MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD[J]. Blood, 2018, 131(25): 2846-2855. [13] BETONICO BB, SOARES J, PAIVA I, et al.Cannabidiol enhances intestinal Cb2 receptor expression and activation increasing regulatory T cells and reduces murine acute graft-versus-host disease without interfering with the graft-versus-leukemia response[J]. J Pharmacol Exp Ther, 2021, 377(2): 273-283. [14] YIN S, TANG SQ, LU Y.Research progress on mechanism of neuroprotective effects of cannabidiol[J]. Chin Trad Herb Drugs(中草药), 2014, 45(3): 432-436. [15] GAO BB, WU YK, MA JH, et al.Neuroprotective effect of cannabidiol on acute cerebral hemorrhage in mice and its mechanism[J]. Shandong Med J(山东医药), 2017, 57(4): 34-36. [16] ATALAY S, GEGOTEK A, WRONSKI A, et al.Therapeutic application of cannabidiol on UVA and UVB irradiated rat skin. a proteomic study[J]. J Pharm Biomed Anal, 2021, 192: 113656. [17] MCCOY K.Interaction between cannabinoid system and Toll-like receptors controls inflammation[J]. Mediat Inflamm, 2016, 2016: 5831315. [18] MAJDI F, TAHERI F, SALEHI P, et al.Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol may be effective against methamphetamine induced mitochondrial dysfunction and inflammation by modulation of Toll-like type-4(Toll-like 4) receptors and NF-kappa B signaling[J]. Med Hypoth, 2019, 133: 109371. [19] MOHANNED A, ALGHETAA H, SULTAN M, et al.Administration of delta(9)-tetrahydrocannabinol (THC) post-staphylococcal enterotoxin B exposure protects mice from acute respiratory distress syndrome and toxicity[J]. Fronti Pharm, 2020, 11: 893. [20] DI FORTI M, IYEGBE C, SALLIS H, et al.Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users[J]. Biol Psych, 2012, 72(10): 811-816. [21] ZUARDI A, CRIPPA J, HALLAK J, et al.Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug[J]. Brazil J Med Biol Res, 2006, 39(4): 421-429. [22] SZKUDLAREK H, RODRIGUEZ-RUIZ M, HUDSON R, et al.THC and CBD produce divergent effects on perception and panic behaviours via distinct cortical molecular pathways[J]. Prog Neuro-Psychopharm & Biol Psych, 2021, 104: 110029. [23] BHATTACHARYYA S, SAINSBURY T, ALLEN P, et al.Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of delta-9-THC[J]. Psychol Med, 2018, 48(16): 2748-2756. [24] BEGGIATO S, IERACI A, TOMASINI M, et al.Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats[J]. Prog in Neuro-Psychopharm & Biol Psychiatry, 2020, 100: 109883. [25] GIBULA-TARLOWSKA E, WYDRA K, KOTLINSKA J.Deleterious effects of ethanol, delta(9)-tetrahydrocannabinol (THC), and their combination on the spatial memory and cognitive flexibility in adolescent and adult male rats in the Barnes maze task[J]. Pharmaceutics, 2020, 12(7): 654. [26] RENARD J, RUSHLOW W, LAVIOLETTE S.Effects of adolescent THC exposure on the prefrontal GABAergic system: implications for schizophrenia-related psychopathology[J]. Front in Psychi, 2018, 9: 281. [27] AFRIN F, CHI M, EAMENS A, et al.Can Hemp Help? Low-THC cannabis and Non-THC cannabinoids for the treatment of cancer[J]. Cancers, 2020, 12(4): 1033. [28] LI HY, YANG CP, JIN HT.Research progress of target related toxicity of anti-tumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 152-157. [29] ANDREWS P, NAYLOR R, Joss R.Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies[J]. Support Care Cancer, 1998, 6(3): 197-203. [30] DARMAIN N, WANG Y, ABAD J, et al.Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists[J]. Brain Res, 2008, 1214: 58-72. [31] DARMAIN N, BELKACEMI L, ZHONG W.Delta(9)-THC and related cannabinoids suppress substance P- induced neurokinin NK1-receptor-mediated vomiting via activation of cannabinoid CB1 receptor[J]. Eur J Pharm, 2019, 865: 172806. [32] CHAVES C, BITTENCOURT P, PELEGRINI A.Ingestion of a THC-rich cannabis oil in people with fibromyalgia: A randomized, double-blind, placebo-controlled clinical trial[J]. Pain Med, 2020, 21(10): 2212-2218. [33] LINHER-MELVILLE K, ZHU Y, SIDHU J, et al.Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Delta 9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination[J]. PLOS One, 2020, 15(6): e0234176. [34] ATWAL N, CASSEY S, MITCHELL V, et al.THC and gabapentin interactions in a mouse neuropathic pain model[J]. Neuropharm, 2019, 144: 115-121. [35] GIACOPPO S, BRAMANTI P, MAZZON E.Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation[J]. Multip Scler and Related Disord, 2017, 17: 22-31. [36] LYU Y, KOPCHO S, MOHAN M, et al.Long-term low-dose delta-9-tetrahydrocannbinol (THC) administration to simian immunodeficiency virus (SIV) infected rhesus macaques stimulates the release of bioactive blood extracellular vesicles (EVs) that induce divergent structural adaptations and signaling cues[J]. Cells, 2020, 9(10): 2243. [37] NACHNANI R, RAUP-KONSAVAGE W, VRANA K.The pharmacological case for cannabigerol[J]. J Pharm Exper Therap, 2021, 376(2): 204-212. [38] CASCIO M, GAUSON L, STEVENSON L, et al.Evidence that the plant cannabinoid cannabigerol is a highly potent alpha(2)-adrenoceptor agonist and moderately potent 5HT(1A) receptor antagonist[J]. Brit J Pharm, 2010, 159(1): 129-141. [39] DI GIACOMO V, CHIAVAROLI A, ORLANDO G, et al.Neuroprotective and neuromodulatory effects induced by cannabidiol and cannabigerol in rat Hypo-E22 cells and isolated hypothalamus[J]. Antioxid, 2020, 9(1): 71. [40] HUI RS, YANG XQ.Cannabis and fungal infections[J]. Chin J Mycol(中国真菌学杂志), 2009, 4(5): 317-320. [41] PINZI L, LHERBET C, BALTAS M, et al.In silico repositioning of cannabigerol as a novel inhibitor of the enoyl acyl carrier protein (ACP) reductase (InhA)[J]. Molecules, 2019, 24(14): 2567. [42] FENG JZ, LIU SH, FENG JF, et al.Research progress on the causes and preventions of metabolic syndrome[J]. J Inner Mongolia Univ Nationalities (Nat Sci)(内蒙古民族大学学报自然科学版), 2020, 35(6): 525-528. [43] ESPOSITO G, SCUDERI C, VALENZA M, et al.Cannabidiol reduces Ab- induced neuroinflammation and promotes hippocampal neurogenesis through PPAR gamma involvement[J]. PLOS One, 2011, 6(12): e28668. [44] D’ANIELLO E, FELLOUS T, IANNOTTI F, et al. Identification and characterization of phytocannabinoids as novel dual PPAR alpha/gamma agonists by a computational and in vitro experimental approach[J]. Biochim Et Biophys Acta-General Subj, 2019, 1863(3): 586-597. [45] BORRELLI F, FASOLINO I, ROMANO B, et al.Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease[J]. Biochem Pharm, 2013, 85(9): 1306-1316. [46] PAGANO E, IANNOTTI F, PISCITELLI F, et al.Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation[J]. Phytother Res, 2021, 35(1): 517-529. [47] LAH T, NOVAK M, ALMIDON M, et al.Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma[J]. Cells, 2021, 10(2): 340. |